Paracrine mechanisms of endothelial progenitor cells in vascular repair

xlomafota13 shared this article with you from Inoreader Paracrine mechanisms of endothelial progenitor cells in vascular repair Via histochem Acta Histochem. 2021 Dec 17;124(1):151833. doi: 10.1016/j.acthis.2021.151833. Online ahead of print. ABSTRACT Endothelial progenitor cells (EPCs) play an important role in repairing damaged blood vessels and promoting neovascularization. However, the specific mechanism of EPCs promoting vascular repair is still unclear. Currently, there are two different views on the repair of damaged vessels by EPCs, one is that EPCs can directly differentiate into endothelial cells (ECs) a nd integrate into injured vessels, the other is that EPCs act on cells and blood vessels by releasing paracrine substances. But more evidence now supports the latter. Therefore, the paracrine mechanisms of EPCs are worth further study. This review describes the substances secreted by EPCs, some applications based on paracrine effects of EPCs, and the studies of paracrine mechanisms in cardiovascular diseases--all of these are to support the view that EPCs repair blood vessels through paracrine effects rather than integrating directly into damaged vessels. PMID:34929523 | DOI:10.1016/j.acthis.2021.151833 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Reconstruction of midline abdominal defects with a deep inferior epigastric artery keystone-type perforator flap

xlomafota13 shared this article with you from Inoreader Reconstruction of midline abdominal defects with a deep inferior epigastric artery keystone-type perforator flap Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Dec 7:S1748-6815(21)00650-1. doi: 10.1016/j.bjps.2021.11.103. Online ahead of print. NO ABSTRACT PMID:34930700 | DOI:10.1016/j.bjps.2021.11.103 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Efficacy and Safety of External Volume Expansion (EVE) on Fat Grafting: A Systematic Review and Single-Arm Meta-Analysis

xlomafota13 shared this article with you from Inoreader Efficacy and Safety of External Volume Expansion (EVE) on Fat Grafting: A Systematic Review and Single-Arm Meta-Analysis Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Nov 16:S1748-6815(21)00576-3. doi: 10.1016/j.bjps.2021.11.032. Online ahead of print. ABSTRACT BACKGROUND: The autologous fat grafting is commonly used for reconstructive or aesthetic purposes. However, due to the huge variation in methods, its retention rate varies a lot. External volume expansion (EVE) has been used to treat recipient sites of fat grafting. Concerns have been raised regarding its efficacy and safety. METHODS: We have searched PubMed, EMBASE, and the Cochrane Library for studies on EVE-assisted fat grafting published from 2000 to 2020. A meta-analysis was conducted to pool the retention rate. The incidence of complications was assessed for reconstructive or aesthetic purposes. RESULTS: The 11 included studies involved 1152 patients with operations on 1794 breasts. Four studies were included in the meta-analysis. The pooled retention rate was 65% [95%CI 49, 79]. Eight stu dies reported the complications. The total complication incidence was 34%, which is 35% for the aesthetic group and 33% for the reconstructive group. The complication rate was not obviously different between the two groups. CONCLUSIONS: The study shows that the EVE-assisted fat grafting has better retention rate than traditional fat grafting. However, the data showed that the complication rate was much higher in the EVE-assisted group. PMID:34930704 | DOI:10.1016/j.bjps.2021.11.032 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Filler-induced complications of the lips: 10 years experience with intralesional laser treatment and refinements

xlomafota13 shared this article with you from Inoreader Filler-induced complications of the lips: 10 years experience with intralesional laser treatment and refinements Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Nov 15:S1748-6815(21)00586-6. doi: 10.1016/j.bjps.2021.11.042. Online ahead of print. ABSTRACT BACKGROUND: The number of minimally invasive cosmetic procedures has steadily increased every year. In the last decade, the rates of filler injection reactions have also increased. This study presents our experience in the management and treatment of permanent filler complications to the lips. Undoubtedly, in these adverse reactions, the lips are the hallmark that most stigmatizes an unnatural look of the face. METHODS: One hundred and eighty-one patients (168 female and 13 male) with permanent filler complications to the lips were treated from September of 2009 to September of 2019 at the University Hospital of Modena. One hundred and thirty-five patients underwent intralesional laser treatment (ILT). Forty-six patients underwent a stab incision and drainage and 10 of these patients had solid and cal cified nodules and therefore underwent a combined technique. Thirty-three patients underwent further cosmetic procedures. RESULTS: In 95% of patients there was a clinical improvement of which complete resolution in 38.7% and partial improvement in 34.2% of cases. Nine patients stopped the treatment because they were not satisfied. No patient was considered to have worsened after the treatment. Thirty-three patients underwent further treatments. CONCLUSIONS: A systematic combined approach between antibiotic therapy and treatments (ILT and a stab incision) represents the best therapeutic approach in dealing with permanent fillers complications to the lips. This treatment modality allows both the removal of the foreign material and the inflammatory reaction with low morbidity and little cosmetic disfigurement. Further cosmetic procedures may be applied to improve aesthetic appearance once most of the non-resorbable substance has been removed. PMID:34930702 | DOI:10.1016/j.bjps.2021.11.042 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Knockdown of circular RNA hsa_circ_0062270 suppresses the progression of melanoma via downregulation of CDC45

xlomafota13 shared this article with you from Inoreader Knockdown of circular RNA hsa_circ_0062270 suppresses the progression of melanoma via downregulation of CDC45 Via Cellular and Molecular Biology Histol Histopathol. 2021 Dec 21:18412. doi: 10.14670/HH-18-412. Online ahead of print. ABSTRACT BACKGROUND: Although systemic therapies for melanoma have been improved, the 5-year survival rate of this aggressive cancer remains poor. It has been shown that hsa_circ_0062270 was upregulated in patients with melanoma. However, the relevant mechanism of hsa_circ_0062270 in the progression of melanoma remains unclear. METHODS: The CCK-8, EdU staining, flow cytometry, and transwell assays were used to determine the viability, proliferation, apoptosis and invasion in melanoma cells. An in vivo animal study was performed finally. RESULTS: The level of hsa_circ_0062270 was significantly upregulated in melanoma cells. In addition, hsa_circ_0062270 knockdown markedly inhibited the viability, proliferation, invasion and promoted the apoptosis of melanoma cells. Cell division cycle protein 45 (CDC45) is the host gene of hsa_circ_0062270 , and downregulation of hsa_circ_0062270 notably decreased the expression of CDC45 in melanoma cells. Rescue assays confirmed that hsa_circ_0062270 regulated the growth of melanoma cells through CDC45. Moreover, RIP analysis showed that hsa_circ_0062270 interacted with RNA-binding protein (RBP) EIF4A3. Furthermore, in vivo study indicated that knockdown of hsa_circ_0062270 inhibited the melanoma tumor growth in vivo. CONCLUSIONS: Downregulation of hsa_circ_0062270 can inhibit the progression of melanoma through downregulation of CDC45. Our findings provide biological mechanisms for the use of hsa_circ_0062270 as a biomarker for melanoma and potential therapeutic target. PMID:34931691 | DOI:10.14670/HH-18-412 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.